

ORAL PRESENTATION

Open Access

# Preclinical and translational studies of fenobam, an mGlu5 NAM, for the treatment of pain

Robert W Gereau IV\*, Laura F Cavallone

From Seventh Scientific Meeting of The TMJ Association, Genetic, Epigenetic, and Mechanistic Studies of Temporomandibular Disorders and Overlapping Pain Conditions  
Bethesda, MD, USA. 7-9 September 2014

## Background

Metabotropic glutamate receptor 5 has been suggested by many rodent studies to be a promising target for the development of novel analgesic drugs. The lack of approved compounds has prevented proof-of-concept studies in human subjects. Here we describe preclinical and translational studies of the mGlu5 negative allosteric modulator (NAM), fenobam.

## Materials and methods

Fenobam was tested for analgesic efficacy and toxicity in mouse models. We also tested the plasma levels after oral dosing of fenobam in healthy volunteers, and collected any adverse events following oral dosing compared to placebo.

## Results

The mGlu5 NAM Fenobam is effective in a wide variety of preclinical pain models in mice with no evidence of the development of analgesic tolerance on daily dosing. No obvious toxicities were observed in mice, or in several studies in healthy human volunteers.

## Conclusions

Fenobam has robust analgesic activity and shows a good safety profile. Fenobam therefore represents a useful tool for proof-of-concept studies in human subjects.

## Acknowledgements

This work was supported by grants from the National Institutes of Health (NS48602) to RG.

Published: 15 December 2014

doi:10.1186/1744-8069-10-S1-O3

**Cite this article as:** Gereau IV and Cavallone: Preclinical and translational studies of fenobam, an mGlu5 NAM, for the treatment of pain. *Molecular Pain* 2014 **10**(Suppl 1):O3.

Washington University Pain Center and Department of Anesthesiology,  
Washington University School of Medicine, St Louis, MO 63110, USA



© 2014 Gereau IV and Cavallone; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated.

Submit your next manuscript to BioMed Central  
and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)

